NEW YORK, Nov. 15 (GenomeWeb News) - Shares in Tripos were up 21 percent at $5.46 in mid-afternoon trading as investors cheered news of an extended multimillion-dollar software license agreement with Pfizer.
The companies initially announced a wide area network partnership in January 2001 that Pfizer employ a "broad array" of Tripos' drug-discovery software tools, including the SYBYL and UNITY programs.
Registering provides access to this and other free content.
Already have an account?Login Now.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.